- •Pediatric Retina
- •Preface
- •1: Development of the Retina
- •1.1 To suppose that the eye . . . could have been formed by natural selection, seems, I freely confess, absurd . . .1
- •1.2 Good order is the foundation of all things2
- •1.3 All that you touch you Change. All that Change Changes you3
- •1.4 Men are born with two eyes, but only one tongue, in order that they should see twice as much as they say4
- •1.7 More than Meets the Optic Vesicle6
- •1.9 Focusing on the Fovea: A Marvel of Development
- •1.10 Nature and Books belong to the eyes that see them7
- •References
- •2: Anatomy and Physiology of the Retina
- •2.1 Introduction
- •2.2 Anatomy of the Retina
- •2.2.2 Cellular Organization of the Retina
- •2.2.2.1 Retinal Pigment Epithelium
- •2.2.2.2 Photoreceptors
- •2.2.2.3 Interneuron Cells
- •2.2.2.4 Ganglion Cells
- •2.2.2.5 Glial Cells
- •2.2.3.1 Bruch’s Membrane
- •2.2.3.2 Retinal Pigment Epithelium
- •2.2.3.3 Photoreceptor Layer
- •2.2.3.4 External Limiting Membrane
- •2.2.3.5 Outer Nuclear Layer
- •2.2.3.6 Outer Plexiform Layer
- •2.2.3.7 Inner Nuclear Layer
- •2.2.3.8 Inner Plexiform Layer
- •2.2.3.9 Ganglion Cell Layer
- •2.2.3.10 Nerve Fiber Layer
- •2.2.5 Blood Supply of the Retina
- •2.2.5.1 Choroidal Circulation
- •2.2.5.2 Hyaloid Circulation
- •2.2.5.3 Retinal Circulation
- •2.2.5.5 Regulation of Blood Flow to the Retina
- •2.2.6 Optic Nerve
- •2.2.6.1 Physiology and Development
- •2.3 Physiology of the Retina
- •2.3.1 The Retinal Pigment Epithelium
- •2.3.3 Image-Forming Visual System
- •2.3.3.1 Detection of Photons by Visual Pigment in the Photoreceptor Cell
- •2.3.3.2 Light Activation of the Photopigment
- •2.3.4 Nonimage-Forming Visual System
- •2.3.5 Targets of Retinal Projections
- •2.4 Retinal Development
- •2.4.2 Foveal Development
- •References
- •3.1 Full-Field ERG
- •3.1.1.1 Rod Response
- •3.1.1.2 Standard Combined Response
- •3.1.1.3 Oscillatory Potentials
- •3.1.1.4 Single-Flash Cone Response
- •3.1.1.5 Light-Adapted Flicker Response
- •3.1.2 Repeat Variability
- •3.1.4 Clinical Uses of the Full-Field ERG
- •3.1.4.2 Stationary Night Blindness
- •3.1.4.3 Enhanced S-Cone Syndrome
- •3.1.4.4 Leber Congenital Amaurosis
- •3.2 Focal and Multifocal ERG
- •References
- •4: Retinopathy of Prematurity (ROP)
- •4.1 Introduction
- •4.2 History
- •4.3 Classification
- •4.4 Incidence
- •4.5 Natural History and Prognosis
- •Disease with Little or No Risk
- •Disease with Moderate Risk
- •Disease with High Risk
- •4.6 Pathogenesis
- •4.7 Screening
- •4.8 Management
- •4.9 Prevention
- •4.10 Interdiction
- •4.11 Corrective Therapy
- •4.12 Mitigation
- •4.13 Medicolegal Considerations
- •4.14 Conclusion
- •References
- •5: Optic Nerve Malformations
- •5.1 Optic Nerve Hypoplasia
- •5.1.1 Overview/Clinical Significance
- •5.1.2 Classification
- •5.1.3 Genetics
- •5.1.4 Pathophysiology
- •5.1.5 Natural History
- •5.1.6 Diagnosis
- •5.1.7 Treatment
- •5.2 Morning Glory Disc Anomaly
- •5.2.1 Overview/Clinical Significance
- •5.2.2 Classification
- •5.2.3 Genetics
- •5.2.4 Pathophysiology
- •5.2.5 Natural History
- •5.2.6 Diagnosis
- •5.2.7 Treatment
- •5.2.8 Associations and Complications
- •5.3 Optic Nerve Head Pits
- •5.3.1 Introduction
- •5.3.2 Overview with Clinical Significance
- •5.3.3 Classification
- •5.3.4 Genetics
- •5.3.5 Pathophysiology
- •5.3.6 Incidence
- •5.3.8 Diagnosis and Diagnostic Aids
- •5.3.9 Treatment
- •5.3.10 Complications and Associations
- •5.4 Optic Disc Coloboma
- •5.4.1 Introduction
- •5.4.2 Genetics
- •5.4.3 Pathophysiology
- •5.4.4 Natural History and Prognosis
- •5.4.5 Diagnosis and Diagnostic Aids
- •5.4.6 Treatment
- •5.5 Optic Nerve Tumor
- •5.5.1 Glioma
- •5.5.1.1 Introduction
- •5.5.2 Overview with Clinical Significance
- •5.5.2.1 Optic Nerve Glioma
- •5.5.2.2 Optic Chiasmal Glioma
- •5.5.3 Pathophysiology
- •5.5.4 Incidence
- •5.5.6 Diagnosis
- •5.5.7 Treatment
- •5.5.8 Social and Family Impact
- •5.6.1 Introduction
- •5.6.3 Pathophysiology
- •5.6.4 Incidence
- •5.6.5 Diagnosis and Diagnostic Aids
- •5.6.6 Treatment
- •5.7 Melanocytoma
- •5.7.1 Introduction
- •5.7.2 Pathophysiology
- •5.7.3 Natural History and Prognosis
- •5.7.4 Diagnosis and Diagnostic Aids
- •5.7.5 Treatment
- •5.8 Metastatic Tumors: Leukemia
- •5.8.1 Introduction
- •5.8.2 Pathophysiology
- •5.8.3 Natural History and Prognosis
- •5.8.4 Treatment
- •5.8.4.1 Other Elevated Disc Anomalies
- •5.9 Drusen
- •5.9.1 Introduction
- •5.9.2 Pathophysiology
- •5.9.3 Natural History and Prognosis
- •5.9.4 Diagnosis and Diagnostic Aids
- •5.10 Hyperopia
- •5.11 Persistence of the Hyaloid System
- •5.12 Tilted Disc
- •5.12.1 Introduction
- •5.12.2 Historical Context
- •5.12.3 Overview with Clinical Significance
- •5.12.4 Genetics
- •5.12.5 Pathophysiology
- •5.12.6 Incidence
- •5.13 Myelinated Nerve Fibers
- •5.13.1 Introduction
- •5.13.2 Genetics
- •5.13.3 Pathophysiology
- •5.13.4 Incidence
- •References
- •6.1.1 Albinism
- •6.1.1.1 Disorders Specific to Melanosomes
- •Hermansky–Pudlak Syndrome
- •Chediak–Higashi Syndrome
- •Diagnosis and Treatment
- •6.1.2 Gyrate Atrophy
- •6.1.3 Cystinosis
- •6.1.3.1 Primary Hyperoxaluria
- •6.2.1 The Gangliosidoses
- •6.2.2 GM1 Gangliosidosis
- •6.2.3 GM2 Gangliosidosis
- •6.2.3.1 Tay–Sachs Disease
- •6.2.4 Sandhoff Disease
- •6.2.5 Niemann–Pick Disease
- •6.2.7 Type C Niemann–Pick Disease
- •6.2.8 Fabry Disease
- •6.2.9 Farber Lipogranulomatosis
- •6.2.10 The Mucopolysaccharidoses
- •6.2.10.1.1 MPS I H: Hurler Syndrome
- •6.2.10.1.2 MPS I S: Scheie Syndrome
- •6.2.10.1.3 MPS I H/S: Hurler–Scheie Syndrome
- •6.2.10.2 MPS II: Hunter Syndrome
- •6.2.10.3 MPS III: Sanfilippo Syndrome
- •6.2.10.4 MPS IV: Morquio Syndrome
- •6.2.10.5 MPS VI: Maroteaux–Lamy Syndrome
- •6.2.10.6 MPS VII: Sly Syndrome
- •6.3 Disorders of Glycoprotein
- •6.3.1 Sialidosis
- •6.4 Disorders of Peroxisomes
- •6.4.1 Refsum Disease
- •References
- •7: Phacomatoses
- •7.1 Introduction
- •7.2 Neurofibromatosis
- •7.2.1 Neurofibromatosis Type 1
- •7.2.1.1 Introduction
- •7.2.1.2 Historical Context
- •7.2.1.3 Overview with Clinical Significance
- •7.2.1.4 Genetics
- •7.2.1.5 Natural History and Prognosis
- •7.2.1.6 Signs and Symptoms
- •7.2.2 Ocular Manifestations
- •7.2.2.1 Lisch Nodules
- •7.2.2.2 Optic Pathway Glioma
- •7.2.2.3 Neurofibroma of the Eyelid and Orbit
- •7.2.3 Systemic Manifestations
- •7.2.3.1 Café-au-lait Spot
- •7.2.3.2 Neurofibroma
- •7.2.3.3 CNS Abnormality
- •Diagnosis and Diagnostic Aids
- •Treatment
- •Social and Family Impact
- •7.2.4 Neurofibromatosis Type 2 (NF2)
- •7.2.4.1 Introduction
- •7.2.4.2 Historical Context
- •7.2.4.3 Overview with Clinical Significance
- •7.2.4.4 Classification
- •7.2.4.5 Genetics
- •7.2.4.6 Incidence
- •7.2.4.7 Natural History and Prognosis
- •7.2.4.8 Signs and Symptoms
- •Ocular Findings
- •Systemic Findings
- •Vestibular Schwannoma
- •Diagnosis and Diagnostic Aids
- •Treatment
- •Complications and Associations
- •Social and Family Impact
- •7.3 Von Hippel–Lindau Disease
- •7.3.1 Introduction
- •7.3.2 Historical Context
- •7.3.3 Overview with Clinical Significance
- •7.3.4 Classification
- •7.3.5 Genetics
- •7.3.6 Pathophysiology
- •7.3.7 Incidence
- •7.3.8 Natural History and Prognosis
- •7.3.9 Signs and Symptoms
- •7.3.9.1 Ocular Manifestations
- •Retinal Capillary Hemangioma
- •7.3.9.2 Systemic Manifestations
- •CNS Hemangioma
- •Renal Cell Carcinoma
- •Pheochromocytoma
- •Pancreatic Cystadenoma and Islet Cell Tumors
- •Epididymis Cystadenoma
- •7.3.10 Diagnosis and Diagnostic Aids
- •7.3.10.1 Coats’ Disease
- •7.3.10.2 Racemose Hemangioma
- •7.3.10.3 Retinal Cavernous Hemangioma
- •7.3.10.4 Retinal Macroaneurysm
- •7.3.10.5 Vasoproliferative Tumor
- •7.3.11 Fluorescein Angiography
- •7.3.12 Indocyanine Green Angiography
- •7.3.13 Ultrasonography
- •7.3.14 Magnetic Resonance Imaging
- •7.3.16 Treatment
- •7.3.17 Observation
- •7.3.18 Laser Photocoagulation
- •7.3.19 Cryotherapy
- •7.3.21 Plaque Radiotherapy
- •7.3.22 Proton Beam Radiotherapy
- •7.3.24 Enucleation
- •7.3.25 Social and Family Impact
- •7.4 Tuberous Sclerosis Complex
- •7.4.1 Introduction
- •7.4.2 Historical Context
- •7.4.3 Overview with Clinical Significance
- •7.4.4 Classification
- •7.4.5 Genetics
- •7.4.6 Incidence
- •7.4.7 Natural History and Prognosis
- •7.4.8 Signs and Symptoms
- •7.4.8.1 Ocular Findings
- •Retinal Astrocytic Hamartoma
- •7.4.8.2 Systemic Findings
- •Dermatologic Manifestations
- •Neurologic Manifestations
- •Visceral Manifestations
- •Diagnosis and Diagnostic Aids
- •Treatment
- •Social and Family Impact
- •7.5 Sturge-Weber Syndrome
- •7.5.1 Introduction
- •7.5.2 Historical Context
- •7.5.3 Overview with Clinical Significance
- •7.5.4 Incidence
- •7.5.5 Genetics
- •7.5.6 Pathophysiology
- •7.5.7 Natural History and Prognosis
- •7.5.8 Signs and Symptoms
- •7.5.8.1 Diffuse Choroidal Hemangioma
- •7.5.8.2 Glaucoma
- •7.5.8.3 Nevus Flammeus
- •7.5.8.4 Leptomeningeal Hemangiomatosis
- •7.5.8.5 Diagnosis and Diagnostic Aids
- •7.5.8.6 Treatment
- •7.5.8.7 Social and Family Impact
- •7.6 Wyburn-Mason Syndrome
- •7.6.1 Introduction
- •7.6.2 Historical Context
- •7.6.3 Overview with Clinical Significance
- •7.6.4 Classification
- •7.6.5 Genetics
- •7.6.6 Pathophysiology
- •7.6.7 Natural History and Prognosis
- •7.6.8 Signs and Symptoms
- •7.6.8.1 Ocular Findings
- •Retinal Arteriovenous Malformation
- •Diagnosis and Diagnostic Aids
- •Treatment
- •7.6.9 Ataxia Telangiectasia
- •7.6.9.1 Introduction
- •7.6.9.2 Historical Context
- •7.6.9.3 Overview with Clinical Significance
- •7.6.9.4 Classification
- •7.6.9.5 Genetics
- •7.6.9.6 Incidence
- •7.6.9.7 Natural History and Prognosis
- •7.6.9.8 Signs and Symptoms
- •7.6.9.9 Diagnosis and Diagnostic Aids
- •7.6.9.10 Treatment
- •7.6.9.11 Social and Family Impact
- •7.7 Retinal Caverous Hemangioma
- •7.7.1 Introduction
- •7.7.2 Historical Context
- •7.7.3 Overview with Clinical Significance
- •7.7.4 Genetics
- •7.7.5 Incidence
- •7.7.6 Natural History and Prognosis
- •7.7.7 Signs and Symptoms
- •7.7.7.1 Ocular Findings
- •7.7.7.2 Systemic Findings
- •Cutaneous Lesions
- •Diagnosis and Diagnostic Aids
- •Treatment
- •References
- •8.1 Introduction
- •8.2 Embryology
- •8.3 Clinical Findings
- •8.3.1 Primary anomalies
- •8.3.2 Secondary findings
- •8.3.3 Differential Diagnosis
- •8.3.3.1 Ancillary Tests
- •8.3.3.2 Prognosis
- •8.3.3.3 Treatment
- •8.4 Practical Surgical Issues
- •8.4.1 The Posterior Surgery
- •References
- •9.1 Introduction
- •9.2 Retinoblastoma Presentation SOP
- •9.2.1 Objective
- •9.2.2 Applicability
- •9.2.3 Scope
- •9.2.4 Clinical Significance
- •9.2.5 Procedures
- •9.2.6 Consequences
- •9.2.7 Related SOPs
- •9.3.1 Objectives
- •9.3.2 Applicability
- •9.3.3 Scope
- •9.3.4 Clinical Significance
- •9.3.5 Procedures
- •9.3.6 Consequences
- •9.3.7 Related SOPs
- •9.4 Genetics of Retinoblastoma SOP
- •9.4.1 Objective
- •9.4.2 Applicability
- •9.4.3 Scope
- •9.4.4 Clinical Significance
- •9.4.5 Procedure
- •9.4.6 Consequences
- •9.4.7 Related SOPs
- •9.5 Screening of Relatives SOP
- •9.5.1 Objective
- •9.5.2 Applicability
- •9.5.3 Scope
- •9.5.4 Clinical Significance
- •9.5.5 Procedure
- •9.5.6 Consequences
- •9.5.7 Related SOPs
- •9.6 Treatment SOP
- •9.7 Enucleation Indications SOP
- •9.7.1 Objective
- •9.7.2 Applicability
- •9.7.3 Scope
- •9.7.4 Clinical Significance
- •9.7.5 Procedure
- •9.7.6 Consequences
- •9.7.7 Related SOPs
- •9.8 Enucleation Technique SOP
- •9.8.1 Objectives
- •9.8.2 Applicability
- •9.8.3 Scope
- •9.8.4 Clinical Significance
- •9.8.5 Procedure
- •9.8.6 Consequences
- •9.8.7 Related SOPs
- •9.9.1 Objectives
- •9.9.2 Applicability
- •9.9.3 Scope
- •9.9.4 Clinical Significance
- •9.9.5 Procedure
- •9.9.6 Consequences
- •9.9.7 Related SOPs
- •9.10 Histopathology Analysis SOP
- •9.10.1 Objectives
- •9.10.2 Applicability
- •9.10.3 Scope
- •9.10.4 Clinical Significance
- •9.10.5 Procedure
- •9.10.6 Consequences
- •9.10.7 Related SOPs
- •9.11 Cryotherapy SOP
- •9.11.1 Objectives
- •9.11.2 Applicability
- •9.11.3 Scope
- •9.11.4 Clinical Significance
- •9.11.5 Procedure
- •9.11.6 Consequences
- •9.11.7 Related SOPs
- •9.12 Laser Therapy SOP
- •9.12.1 Objective
- •9.12.2 Applicability
- •9.12.3 Scope
- •9.12.4 Clinical Significance
- •9.12.5 Procedure
- •9.12.6 Consequences
- •9.12.7 Related SOPs
- •9.13 Local Chemotherapy SOP
- •9.13.1 Objectives
- •9.13.2 Applicability
- •9.13.3 Scope
- •9.13.4 Clinical Significance
- •9.13.5 Procedure
- •9.13.6 Consequences
- •9.13.7 Related SOPs
- •9.14 Systemic Chemotherapy SOP
- •9.14.1 Objectives
- •9.14.2 Applicability
- •9.14.3 Scope
- •9.14.4 Clinical Significance
- •9.14.5 Procedure
- •9.14.6 Consequences
- •9.14.7 Related SOPs
- •9.15 Radiation SOP
- •9.15.1 Objective
- •9.15.2 Applicability
- •9.15.3 Scope
- •9.15.4 Clinical Significance
- •9.15.5 Procedure
- •9.15.6 Consequences
- •9.15.7 Related SOPs
- •9.16.1 Objective
- •9.16.2 Applicability
- •9.16.3 Scope
- •9.16.4 Clinical Significance
- •9.16.5 Procedure
- •9.16.6 Consequences
- •9.16.7 Related SOPs
- •9.17 Follow-Up SOP
- •9.17.1 Objective
- •9.17.2 Applicability
- •9.17.3 Scope
- •9.17.4 Clinical Significance
- •9.17.5 Procedure
- •9.17.6 Consequences
- •9.17.7 Related SOPs
- •References
- •10: Coats’ Disease
- •10.1 Overview
- •10.3 Clinical Aspects
- •10.3.1 Demographics
- •10.3.2 Ocular Findings
- •10.4 Pathology and Pathophysiology
- •10.5 Genetics
- •10.6 Natural History
- •10.8 Management
- •10.9 Systemic Associations
- •10.10 Social and Family Impact
- •10.11 Future Treatment
- •References
- •11.1.1 Stargardt Macular Dystrophy
- •11.1.1.1 Clinical Features: STGD
- •11.1.1.2 Diagnostic Features: STGD
- •11.1.1.3 Differential Diagnosis: STGD
- •11.1.1.4 Inherited Forms: STGD
- •11.1.2 Best Macular Dystrophy
- •11.1.2.1 Clinical Features: BMD
- •11.1.2.2 Diagnostic Features: BMD
- •11.1.2.3 Differential Diagnosis: BMD
- •11.1.2.4 Inherited Forms: BMD
- •11.1.3 Juvenile X-Linked Retinoschisis
- •11.1.3.1 Clinical Features: JXRS
- •11.1.3.2 Diagnostic Features: JXRS
- •11.1.3.3 Differential Diagnosis: JXRS
- •11.1.3.4 Inherited Forms: JXRS
- •11.2.2 Molecular Genetic Testing
- •11.2.3.1 ABCR
- •11.2.3.2 ELOVL4
- •11.2.3.3 PROM1
- •11.2.3.4 BEST-1
- •11.3.1 STGD
- •11.3.3 JXRS
- •11.4.1 STGD Models
- •11.4.2 BMD Models
- •11.4.3 JXRS Models
- •11.5 Phenotypic Diversity
- •11.6 Potential Therapeutics for Juvenile Macular Degenerations
- •References
- •12: Generalized Inherited Retinal Dystrophies
- •12.1 Introduction
- •12.2 Historical Context
- •12.4.1 Retinitis Pigmentosa
- •12.4.1.1 Overview with Clinical Significance
- •12.4.1.2 Genetics
- •12.4.1.3 Pathophysiology
- •12.4.1.4 Prevalence
- •12.4.1.5 Patient History and Evaluation
- •12.4.1.6 Diagnostic Testing
- •12.4.1.7 Treatment
- •12.4.2 Congenital Leber Amaurosis
- •12.4.2.1 Genetics
- •12.4.2.2 Pathophysiology
- •12.4.2.3 Incidence/Prevalence
- •12.4.2.4 Natural History and Prognosis
- •12.4.2.5 Diagnostic Testing
- •12.4.2.6 Treatment
- •12.4.3.1 Genetics
- •12.4.3.2 Pathophysiology
- •12.4.3.3 Incidence
- •12.4.3.4 Natural History and Prognosis
- •12.4.3.5 Diagnostic Testing
- •12.4.3.6 Treatment
- •12.4.3.7 Achromatopsia
- •12.4.4.1 Genetics
- •12.4.4.2 Pathophysiology
- •12.4.4.3 Incidence
- •12.4.4.4 Evaluation and Prognosis
- •12.4.4.5 Diagnostic Testing
- •12.4.4.6 Treatment
- •12.4.4.7 Complications and Disease Associations
- •12.4.4.8 Social Considerations
- •References
- •13: Vitreoretinal Dystrophies
- •13.1 Stickler Syndrome
- •13.1.1 Introduction
- •13.1.2 Historical Context
- •13.1.3 Overview with Clinical Significance
- •13.1.4 Classification
- •13.1.5 Genetics
- •13.1.6 Pathophysiology
- •13.1.7 Incidence
- •13.1.8 Natural History and Prognosis of STK (Signs, Symptoms, Timing, etc.)
- •13.1.9 Diagnosis and Diagnostic Aids
- •13.1.10 Treatment
- •13.1.11 Complications and Associations
- •13.1.12 Social and Family Impact
- •13.2 Wagner Disease
- •13.2.1 Introduction
- •13.2.2 Historical Context
- •13.2.3 Overview with Clinical Significance
- •13.2.4 Classification
- •13.2.5 Genetics
- •13.2.6 Pathophysiology
- •13.2.7 Incidence
- •13.2.9 Diagnosis and Diagnostic Aids
- •13.2.10 Treatment
- •13.2.11 Complications and Associations
- •13.2.12 Social and Family Impact
- •13.3 Juvenile X-Linked Retinoschisis
- •13.3.1 Introduction
- •13.3.2 Historical Context
- •13.3.3 Overview with Clinical Significance
- •13.3.4 Classification
- •13.3.5 Genetics
- •13.3.6 Pathophysiology
- •13.3.7 Incidence
- •13.3.9 Diagnosis and Diagnostic Aids
- •13.3.10 Treatment
- •13.3.11 Complications and Associations
- •13.3.12 Social and Family Impact
- •13.4.1 Introduction
- •13.4.2 Historical Context
- •13.4.3 Overview with Clinical Significance
- •13.4.4 Classification
- •13.4.5 Genetics
- •13.4.6 Pathophysiology
- •13.4.7 Incidence
- •13.4.9 Diagnosis and Diagnostic Aids
- •13.4.10 Treatment
- •13.4.11 Complications and Associations
- •13.4.12 Social and Family Impact
- •13.5 Goldmann-Favre Syndrome
- •13.5.1 Introduction
- •13.5.2 Historical Context
- •13.5.3 Overview with Clinical Significance
- •13.5.4 Classification
- •13.5.5 Genetics
- •13.5.6 Pathophysiology
- •13.5.7 Incidence
- •13.5.9 Diagnosis and Diagnostic Aids
- •13.5.10 Treatment
- •13.5.11 Complications and Associations
- •13.5.12 Social and Family Impact
- •13.6 Incontinentia Pigmenti (IP)
- •13.6.1 Introduction
- •13.6.2 Historical Context
- •13.6.3 Overview with Clinical Significance
- •13.6.4 Classification
- •13.6.5 Genetics
- •13.6.6 Pathophysiology
- •13.6.7 Incidence
- •13.6.9 Diagnosis and Diagnostic Aids
- •13.6.10 Treatment
- •13.6.11 Complications and Associations
- •13.6.12 Social and Family Impact
- •13.7.9 Diagnosis and Diagnostic Aids
- •13.7.10 Treatment
- •13.7.11 Complications and Associations
- •13.7.12 Social and Family Impact
- •References
- •14.1 Introduction
- •14.2 Clinical Course
- •14.3 Differential Diagnosis
- •14.4 Pathology
- •14.5 Selected Conditions
- •14.6 Treatment
- •References
- •15: Proliferative Retinopathies in Children
- •15.1 Introduction
- •15.2 Historical Context
- •15.3 Overview with Clinical Significance
- •15.4 Classification
- •15.5 Genetics (table 15.1)
- •15.5.1 Pathophysiology
- •15.5.2 Natural History and Prognosis
- •15.5.3 Diabetes Mellitus
- •15.5.4 Sickle Cell Disease
- •15.5.5 Incontinentia Pigmenti
- •15.6 Complications and Associations
- •15.7 Social and Family Impact
- •References
- •16: Infectious Diseases of the Pediatric Retina
- •16.1 Introduction
- •16.2 Protozoal Diseases
- •16.2.1 Toxoplasma gondii
- •16.2.1.1 Life Cycle and Transmission
- •16.2.1.2 Epidemiology
- •16.2.1.3 Congenital Infection
- •16.2.1.4 Ocular Disease
- •16.2.1.5 Immunocompromised Patients
- •16.2.1.6 Diagnosis of Ocular Toxoplasmosis
- •16.2.1.7 Treatment
- •16.2.1.8 Treatment in Special Situations
- •16.3 Viral Diseases
- •16.3.1 Cytomegalovirus Retinitis
- •16.3.1.1 Congenital CMV Infection
- •16.3.1.2 Ocular Manifestations
- •16.3.1.3 Acquired CMV Infection
- •16.3.1.4 Ocular Disease
- •16.3.1.5 Pathology
- •16.3.1.6 Diagnosis
- •16.3.1.7 Therapy
- •16.3.2 Varicella Zoster Virus
- •16.3.2.1 Ocular Manifestations
- •16.3.3 Herpes Simplex Virus
- •16.3.3.1 Ocular Disease
- •16.3.4 Acute Retinal Necrosis
- •16.3.4.1 Clinical Presentation
- •16.3.4.2 Diagnosis
- •16.3.4.3 Treatment
- •16.3.5 HIV Infection
- •16.3.5.1 Ocular Manifestations
- •16.3.5.2 Noninfectious HIV Microangiopathy
- •16.3.6 Measles
- •16.3.7 Rubella
- •16.3.7.1 Congenital Rubella Syndrome
- •16.4 Parasitic Infection
- •16.4.1 Toxocariasis
- •16.4.1.1 Ocular Involvement
- •16.4.1.2 Diagnosis
- •16.4.1.3 Differential Diagnosis
- •16.4.1.4 Treatment
- •16.4.2 Onchocerciasis
- •16.4.2.1 Ocular Manifestations
- •16.4.2.2 Diagnosis and Treatment
- •16.5 Bacterial Diseases
- •16.5.1 Syphilis
- •16.5.1.1 Clinical Manifestations
- •16.5.1.2 Congenital Syphilis
- •16.5.1.3 Acquired Syphilis
- •16.5.1.4 Diagnosis
- •16.5.1.5 Syphilis and AIDS
- •16.5.1.6 Treatment
- •16.5.2 Tuberculosis
- •16.5.2.1 Ocular Manifestation
- •16.5.2.2 Diagnosis
- •16.5.2.3 Tuberculosis and AIDS
- •16.5.2.4 Treatment
- •16.6 Rare Childhood Bacterial Diseases
- •16.6.1 Brucellosis
- •16.6.2 Leptospirosis
- •16.6.3 Lyme Disease
- •16.6.4 Cat Scratch Disease
- •16.7 Fungal Disease
- •16.7.1 Histoplasmosis
- •16.7.1.1 Ocular Histoplasmosis Syndrome (OHS)
- •16.7.1.2 Diagnosis and Treatment
- •16.7.2 Fungal Endophthalmitis
- •16.7.2.1 Endogenous Fungal Endophthalmitis
- •Candidiasis
- •Ocular Features
- •Diagnosis and Treatment
- •Rare Causes of Endogenous Endophthalmitis
- •Aspergillosis
- •Cryptococcosis
- •Histoplasmosis
- •Pneumocystis carinii
- •North American Blastomycosis
- •Coccidiomycosis
- •Other Fungal Infections
- •16.7.2.2 Exogenous Fungal Endophthalmitis
- •16.8 Rickettsial Disease
- •References
- •17.1 Introduction
- •17.2 Age of Victims
- •17.4 Perpetrators
- •17.5 Brain Injury
- •17.6 Skeletal Injuries
- •17.7 Acute Ophthalmic Findings
- •17.8 Dating of Retinal Hemorrhages
- •17.9 Treatment of Retinal Hemorrhages
- •17.10 Late Ophthalmic Findings
- •17.13 The Role of the Ophthalmologist
- •References
- •18: Pediatric Retinal Trauma
- •18.1 Introduction
- •18.2 Epidemiology
- •18.3 Etiology of Trauma
- •18.3.1 Sports
- •18.3.2 Assault
- •18.3.3 Birth Trauma
- •18.3.4 Projectile Injury
- •18.3.5 Miscellaneous Causes
- •18.3.6 Sympathetic Ophthalmia
- •18.4 Closed Globe Injuries
- •18.4.1 Traumatic Macular Hole
- •18.4.2 Commotio Retinae
- •References
- •19: Pediatric Uveitis
- •19.1 General Introduction
- •19.2 Classification
- •19.3 Social and Family Impact
- •19.4 Noninfectious
- •19.4.1 Juvenile Rheumatoid Arthritis
- •19.4.1.1 Historical Context
- •19.4.1.2 Clinical Findings/Natural History
- •Subtypes of JRA (Table 19.2) .
- •Screening Guidelines
- •Pathophysiology
- •Diagnosis/Treatment
- •Genetics
- •Complications
- •19.4.2 HLA-B27-Associated Uveitis
- •19.4.2.1 Historical Context
- •19.4.2.2 Clinical Findings/Natural History
- •Pathophysiology/Genetics
- •Diagnosis/Treatment/Complications
- •19.4.3 Tub ulointerstitial Nephritis and Uveitis (TINU)
- •19.4.3.1 Historical Context
- •19.4.3.2 Clinical Findings/Natural History
- •Pathophysiology/Genetics
- •Diagnosis/Treatment/Complications
- •19.4.4 Sarcoidosis
- •19.4.4.1 Historical Context
- •19.4.4.2 Clinical Findings/Natural History
- •Pathophysiology
- •Genetics
- •Diagnosis/Treatment/Complications
- •19.4.5 Pars Planitis
- •19.4.5.1 Historical Context
- •19.4.5.2 Clinical Findings/Natural History
- •Pathophysiology/Genetics
- •Diagnosis
- •Treatment
- •Step 1
- •Step 2
- •Step 3
- •Step 4
- •Complications
- •19.5 Infectious
- •19.5.1 Toxoplasmosis
- •19.5.1.1 Historical Context/Pathophysiology
- •19.5.1.2 Clinical Findings/Natural History
- •Genetics
- •Diagnosis/Treatment/Complications
- •19.5.2 Toxocariasis
- •19.5.2.1 Historical Context/Pathophysiology
- •19.5.2.2 Clinical Findings/Natural History
- •Genetics
- •Diagnosis/Treatment/Complications
- •19.5.3 Bartonella henselae
- •19.5.3.1 Historical Context/Pathophysiology
- •19.5.3.2 Clinical Findings/Natural History
- •Genetics
- •Diagnosis/Treatment/Complications
- •19.5.4.1 Historical Context/Pathophysiology
- •19.5.4.2 Clinical Findings/Natural History
- •Genetics
- •Diagnosis/Treatment/Complications
- •19.5.5 Congenital Ocular Syphilis
- •19.5.5.1 Historical Context/Pathophysiology
- •19.5.5.2 Clinical Findings/Natural History
- •Genetics
- •Diagnosis/Treatment/Complications
- •References
- •Index
8 Persistent Hyperplastic Primary Vitreous (PHPV) |
193 |
|
|
has demonstrated at this age that the hyaloid artery is completely regressed in 20% of fetuses, incompletely in 20%, and continues to have blood in 60% [14, 15].
During the seventh month, blood flow in the hyaloid artery has ceased and the artery has become very narrow [6, 12]. By 29 weeks, no hyaloid artery system can be seen on ultrasound [14]. The posterior portion of the hyaloid artery begins to regress [2] and by the eighth month, the hyaloid artery has lost its connection to the optic nerve [6, 12]. The vessels curl and form corkscrews behind the lens after losing the proximal connection [6]. The anterior portion of the hyaloid artery drops inferiorly within Cloquet’s canal. By the middle of the eighth month, the central loops of the pupillary membrane have atrophied and the lesser circle of the iris is the sole channel of the return of blood reaching the central portion of the iris [6].
8.3 Clinical Findings
The clinical findings of PFV can affect virtually any structure in the eye and can range in severity from an isolated Bergmeister papilla to a microphthalmic eye with multiple anomalies. The persistent fetal vessels can lead to either primary or secondary malformations which present at birth or years later.
8.3.1 Primary anomalies
These findings are directly caused by the persistent fetal vessels interfering with normal ocular development.
Persistent pupillary membrane: This is a common clinical finding related to persistence of the anterior TVL. These membranes have been noted in up to 95% of normal newborns and disappear shortly after birth [4, 6, 16]. Normally, these vessels begin to regress during the fifth month of gestation [6], however, their persistence can give rise to numerous clinical findings including irregular looping vessels, correctopia, and congenital ectropion uveae [4].
Iridohyaloid blood vessels: (Fig. 8.3) Persistence of the iridohyaloid vessels or lateral TVL may create numerous signs including prominent radial vessels in the iris stroma [4, 12], a notch in the pupil (which can be subtle), or
Fig. 8.3 Posterior PFV. Note the prominent radial vessels in the iris stroma
anastamoses with a vascular retrolental membrane (RLM) [4, 8]. Additionally, persistence of the iridohyaloid vessels may impede proper lens-zonule development. Goldberg noted an association of persistent iridohyaloid blood vessels with congenital absence of the fovea and stressed that eyes with PFV may have seemingly unrelated anterior and posterior findings [12].
Mittendorf dot: The termination of the hyaloid artery. It is seen in 0.7–2% of normal population and is of no visual significance [4].
RLM: (Fig. 8.4 and 8.5) This finding is caused by persistence of the posterior TVL and hyaloid system with hyperplasia of surrounding mesoderm [13]. It may occur with a completely regressed hyaloid artery.
Fig. 8.4 Shows a 3 mm white retrolental plaque in the typical off-axis position
194 |
B.M. Buerk et al. |
|
|
Fig. 8.5 A narrow slit beam clearly locates the white tissue to the retrolental space with extensions to the posterior capsule. This is the same plaque seen in Fig. 8.4
The tissue is typically thickest centrally [1] and has vessels in a radial pattern, which can help distinguish from the more random pattern seen with stage V ROP (retinopathy of prematurity). Goldberg has proposed the term brittle star sign after the marine echinoderm this vascular pattern resembles [4]. The RLM may range from 1 to 6 mm and incorporate ciliary processes and peripheral retina.
Hyaloid artery: The hyaloid artery begins to atrophy during the seventh month of gestation and initially loses its connection to the optic nerve. The vessel then involutes and falls inferiorly into the vitreous from its attachment to the lens. The hyaloid artery can persist in many forms (Fig. 8.6). It can insert into the posterior pole of the lens, or be incorporated into a posterior fibrovascular sheath [17].
Fig. 8.6 Persistant hyaloid artery
Nonattachment of the retina: Also termed congenital retinal fold, this finding is felt to be secondary to persistent attachment of the primary vitreous and blood vesselstoonesideofthedevelopingopticcup.Consequently, the developing secondary vitreous is unable to form a plane to separate the retina and primary vitreous [4]. The retina may be adherent to the ciliary body or dragged centrally into the posterior fibrovascular sheath (Fig. 8.4) [18]. Retinal detachment (RD) has been noted in 56% of patients with PFV [3, 18].
Macular hypoplasia and optic nerve hypoplasia: It is unclear why the disruption of fetal vasculature regression causes these findings. The presence of macular or optic nerve hypoplasia has been noted to portend a poor visual prognosis [19].
Bergmeister papilla: This can occur in isolation in many normal subjects or associated with other remnants of the fetal vasculature.
Microphthalmia: Seen in 66–84% of eyes [3, 18], it can range from a normal appearing globe with a small cornea, to a very small eye. The globe however may be normal size or even buphthalmic, if congenital glaucoma develops [12, 18].
8.3.2 Secondary findings
The structural changes caused by PFV can lead to numerous secondary complications. The sequelae of these primary anomalies can manifest from months to years after birth.
Cornea: The cornea may become opaque in PFV usually due to glaucoma or phthisis bulbi. Additionally, a central defect in Descemet’s membrane leading to a Peter’s like leukoma has been reported in PFV [18].
Anterior chamber: May be shallow and lead to angle closure glaucoma due to intumescent lens formation [20].
Cataract: Many authors have noted the lens in eyes with PFV is initially clear, and becomes cataractous in the first few postnatal months [20]. Pollard commented that the posterior lens capsule is absent in 50% of patients with PFV. This absence leads to migration of lens epithelial cells, absorption of lens material and replacement of the lens with mesenchymal [18] or adipose tissue [20].
